| Trial ID: | L0013 |
| Source ID: | NCT02474810
|
| Associated Drug: |
Alteplase
|
| Title: |
Intensive Versus Standard Hemodialysis CVC Dysfunction Protocol
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Renal Insufficiency
|
| Interventions: |
DRUG: Alteplase
|
| Outcome Measures: |
Primary: Alteplase use, Incident rate of rt-PA uses includes the numerator which will consist of the number of HD sessions during which a patient was administered rt-PA for catheter malfunction and the denominator will be the time period at risk in catheter days., 9 months | Secondary: Rate of bacteremia, Rate of bacteremia will include the numberator which will consit of the number of definite or probable catheter related bacteremia events and the decominator will be the time period at risk in catheter days., 9 months|Cost of alteplase, Cost of rt-PA will be calculated per TLD for the study period., 9 months
|
| Sponsor/Collaborators: |
Sponsor: Nova Scotia Health Authority
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
35
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2013-01
|
| Completion Date: |
2015-09
|
| Results First Posted: |
|
| Last Update Posted: |
2024-08-21
|
| Locations: |
Capital Health District Authority, Department of Medicine, Division of Nephrology, Halifax, Nova Scotia, b3h 2y9, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT02474810
|
